Nasdaq

Achieve Life Sciences Announces Planned NDA Submission for Cytisinicline Targeting End of Q2 2025

Achieve Life Sciences, Inc. announced its financial results for Q4 and the year-end 2024, while reaffirming plans to submit a new drug application (NDA) for cytisinicline, a treatment for nicotine ...
Seeking Alpha

Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation

More than 2,000 clinical trial participants contributed to the body of evidence submitted in the NDA demonstrating cytisinicline’s efficacy, safety, and tolerability profile SEATTLE and VANCOUVER, ...
Seeking Alpha

Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission

SEATTLE and VANCOUVER, British Columbia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (ACHV), a late-stage pharmaceutical company committed to the global development and ...
Nasdaq

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

SEATTLE and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the global development and ...